RSV LID deltaM2-2 1030s
Alternative Names: LID ΔM2-2 1030s; RSV LID ΔM2-2 1030s; RSV LID/ΔM2-2/1030sLatest Information Update: 29 Jan 2025
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Class Attenuated vaccines; DNA vaccines; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 29 Jan 2025 RSV LID deltaM2-2 1030s is still in phase I development in Respiratory-syncytial-virus-infections (In infants, Prevention) in USA (Intranasal) (NCT04520659)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants, Prevention) in USA (Intranasal, Drops)
- 20 Aug 2020 National Institute of Allergy and Infectious Diseases and Sanofi plan a phase I trial in Respiratory syncytial virus infections (Prevention, In infants) in USA (NCT04520659)